TY - JOUR
AU1 - Someya, Masanori
AU2 - Tsuchiya, Takaaki
AU3 - Fukushima, Yuki
AU4 - Hasegawa, Tomokazu
AU5 - Hori, Masakazu
AU6 - Kitagawa, Mio
AU7 - Gocho, Toshio
AU8 - Mafune, Shoh
AU9 - Ikeuchi, Yutaro
AU1 - Hirohashi, Yoshihiko
AU1 - Torigoe, Toshihiko
AU1 - Iwasaki, Masahiro
AU1 - Matsuura, Motoki
AU1 - Saito, Tsuyoshi
AU1 - Matsumoto, Yoshihisa
AU1 - Sakata, Koh-ichi
AB - To supplement clinical decision-making in the management of cervical cancer, various prognostic factors, including tumor immune microenvironments, were examined in patients with cervical cancer treated with definitive chemoradiotherapy. We retrospectively analyzed the expression of CD8, FoxP3, HLA-1, PD-L1, and XRCC4 in 100 cases of cervical cancer. The observed tumor immune microenvironments were also classified into three types: inflamed, excluded, and cold type. Less FoxP3+ T cells and cold-type tumor were found to be poor prognostic factors in addition to non-SCC, large pre-treatment tumor volume, and three or less cycles of concurrent chemotherapy based on multivariate analysis. Cold-type tumors had significantly worse prognoses than the other two types, whereas inflamed- and excluded-type tumors showed similar 5-year disease-specific survival (P < 0.001; 0% vs. 60.3% vs. 72.3%). Radiotherapy could overcome the inhibitory immune microenvironment that occurs in excluded type. Individualized combination therapy adapted to pre-treatment tumor immunity may be necessary to improve radiotherapy outcomes in cervical cancer.
TI - Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy
JF - Medical Molecular Morphology
DO - 10.1007/s00795-021-00290-w
DA - 2021-05-08
UR - https://www.deepdyve.com/lp/springer-journals/prediction-of-treatment-response-from-the-microenvironment-of-tumor-nfYzv25MB0
SP - 245
EP - 252
VL - 54
IS - 3
DP - DeepDyve
ER -